Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Raw Materials (2023 - 2024)

Seres Therapeutics' Raw Materials history spans 2 years, with the latest figure at $4.9 million for Q2 2024.

  • For Q2 2024, Raw Materials rose 802.01% year-over-year to $4.9 million; the TTM value through Jun 2024 reached $4.9 million, up 802.01%, while the annual FY2023 figure was $4.4 million, N/A changed from the prior year.
  • Raw Materials for Q2 2024 was $4.9 million at Seres Therapeutics, up from $4.2 million in the prior quarter.
  • Across five years, Raw Materials topped out at $4.9 million in Q2 2024 and bottomed at $547000.0 in Q2 2023.